AAPL vs ABBV: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and AbbVie Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
Apple Inc. · Technology
$260.88
+135.9% upside to fair value
Grade B
High Quality
VS
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
QuantHub Verdict
AAPL has more upside to fair value
(+135.9%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
ABBV |
| Current Price |
$260.88 |
$208.05 |
| Fair Value Estimate |
$615.48 |
$217.50 |
| Upside to Fair Value |
+135.9%
|
+4.5%
|
| Market Cap |
$3,834.4B |
$367.9B |
| Forward P/E |
32.6x
|
14.9x
|
| EV / EBITDA |
25.4x
|
16.7x
|
| Price / Sales |
8.8x
|
6.1x
|
| Price / FCF |
31.1x
|
20.9x
|
| Revenue Growth YoY |
+40.3%
|
+8.6%
|
| Gross Margin |
47.3%
|
83.7%
|
| Operating Margin |
32.4%
|
34.7%
|
| Return on Equity |
159.9%
|
-129.24%
|
| Dividend Yield |
0% |
3.2% |
| FCF Yield |
3.21%
|
4.78%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services with a strong brand and durable competitive advantages. The business quality is high, demonstrated by exceptional profitability metrics including a 159.9% return on equity, 40.3% revenue growth year-over-year, and 53.3% earnings growth year-over-year. Despite these fundamentals, the stock is cu…
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Accumulation Zones
| Metric |
AAPL |
ABBV |
| Zone Low |
$461.61 |
$163.13 |
| Zone High |
$523.16 |
$184.88 |
| In Buy Zone? |
Yes
|
No
|